RxDoctor Payments Data

Joseph Aloise, DO

Adult Medicine · Haddon Heights, NJNPI 1275528564

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Pfizer at 44.4% of the total. Reporting peaked in 2020 at $324 and has fallen 94.5% since, to $18 in 2021.

$660in general payments, 2019–2025

Across 47 payments — averaging $14.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$293
  • AstraZeneca$60
  • GSK$58
  • Eisai Inc.$47
  • Lilly USA, LLC$42
  • Amgen$42
  • plus $119 from 7 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$660 in reported general payments places this provider in the 70th percentile of 48 adult medicine providers in New Jersey.

See all adult medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$36,684
Medicare patients
228
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$22,816
MyrbetriqMirabegron16$6,885
Breo ElliptaFluticasone/Vilanterol15$5,853
Atorvastatin Calcium102$1,810
Levothyroxine Sodium69$902
Omeprazole63$863
Metoprolol Succinate53$821
Losartan Potassium46$721
Fluticasone Propionate27$691
Lisinopril93$689
Gabapentin36$603
Albuterol Sulfate HfaAlbuterol Sulfate23$500
Hydroxyzine Hcl15$492
Sertraline Hcl42$455
Escitalopram Oxalate15$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$293$22,81629 claims
GSKBreo Ellipta$58$5,85315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 adult medicine providers in New Jersey.

Other adult medicine in Haddon Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →